Cerebain Biotech Corp. (CBBT) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
600 ANTON BLVD. COSTA MESA, CA 92626 |
| State of Incorp. | NV |
| Fiscal Year End | June 30 |
| Industry (SIC) | 5047 - Medical, Dental, and Hospital Equipment and Supplies (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 3/31/2019 MRQ | 6/30/2018 | 6/30/2017 | 6/30/2016 | 6/30/2015 | 6/30/2014 | |||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash, cash equivalents, and short-term investments | 65 | 11 | 20 | 0 | 2 | |||
| Cash and cash equivalents | 65 | 11 | 20 | 0 | 2 | |||
| Prepaid expense | 27 | 226 | 476 | 185 | 694 | |||
| Total current assets: | 92 | 237 | 496 | 186 | 696 | |||
| Noncurrent Assets | ||||||||
| Intangible assets, net (including goodwill) | 184 | ✕ | ||||||
| Intangible assets, net (excluding goodwill) | 184 | |||||||
| Other undisclosed noncurrent assets | 134 | |||||||
| Total noncurrent assets: | 184 | 134 | ||||||
| TOTAL ASSETS: | 92 | 237 | 496 | 370 | 830 | |||
| LIABILITIES AND EQUITY | ||||||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued liabilities, including: | 1,453 | 1,101 | 685 | 100 | 50 | |||
| Taxes payable | 94 | 59 | ||||||
| Employee-related liabilities | 216 | 116 | ||||||
| Accounts payable | 1,143 | 926 | 685 | 399 | 133 | |||
| Other undisclosed accounts payable and accrued liabilities | (299) | (83) | ||||||
| Debt | 468 | 100 | 63 | 296 | ||||
| Due to related parties | 350 | 261 | 231 | 530 | 288 | |||
| Other undisclosed current liabilities | 834 | 289 | 114 | 346 | 227 | |||
| Total current liabilities: | 3,105 | 1,751 | 1,092 | 1,271 | 565 | |||
| Noncurrent Liabilities | ||||||||
| Long-term debt and lease obligation | 2,571 | 2,739 | 2,448 | 1,475 | 2,561 | |||
| Long-term debt, excluding current maturities | 2,571 | 2,739 | 2,448 | 1,475 | 2,561 | |||
| Liabilities, other than long-term debt | 144 | |||||||
| Due to related parties | 144 | |||||||
| Other undisclosed noncurrent liabilities | (1,647) | |||||||
| Total noncurrent liabilities: | 2,571 | 2,739 | 2,448 | 1,475 | 1,058 | |||
| Total liabilities: | 5,675 | 4,490 | 3,541 | 2,746 | 1,624 | |||
| Equity | ||||||||
| Equity, attributable to parent | (5,584) | (4,253) | (3,045) | (2,377) | (794) | |||
| Common stock | 9 | 8 | 7 | 5 | 4 | |||
| Additional paid in capital | 26,857 | 23,270 | 8,466 | 6,713 | 5,357 | |||
| Accumulated deficit | (32,450) | (27,531) | (11,518) | (9,094) | (6,155) | |||
| Total equity: | (5,584) | (4,253) | (3,045) | (2,377) | (794) | |||
| TOTAL LIABILITIES AND EQUITY: | 92 | 237 | 496 | 370 | 830 | |||
Income Statement (P&L) ($ in thousands)
| 3/31/2019 TTM | 6/30/2018 | 6/30/2017 | 6/30/2016 | 6/30/2015 | 6/30/2014 | ||
|---|---|---|---|---|---|---|---|
| Revenues (Revenue, Net) | 100 | 100 | 50 | ||||
| Cost of revenue (Cost of Goods and Services Sold) | (8) | (31) | |||||
| Gross profit: | 100 | 100 | 42 | (31) | |||
| Operating expenses | (1,411) | (2,034) | (1,860) | (2,127) | (2,863) | ||
| Other undisclosed operating loss | (3,608) | (14,079) | (605) | (782) | (505) | ||
| Operating loss: | (4,919) | (16,013) | (2,424) | (2,940) | (3,369) | ||
| Nonoperating expense | (13,975) | (505) | |||||
| Other nonoperating expense | (13,979) | (505) | |||||
| Interest and debt expense | (347) | 13,779 | (134) | (201) | (142) | ||
| Loss from continuing operations before equity method investments, income taxes: | (5,266) | (16,209) | (2,557) | (3,140) | (4,016) | ||
| Other undisclosed income from continuing operations before income taxes | 347 | 134 | 201 | 647 | |||
| Loss from continuing operations: | (4,919) | (16,209) | (2,424) | (2,940) | (3,369) | ||
| Loss before gain (loss) on sale of properties: | (4,919) | (16,209) | (2,424) | (2,940) | (3,369) | ||
| Other undisclosed net income | 196 | ||||||
| Net loss available to common stockholders, diluted: | (4,919) | (16,013) | (2,424) | (2,940) | (3,369) | ||
Comprehensive Income ($ in thousands)
| 3/31/2019 TTM | 6/30/2018 | 6/30/2017 | 6/30/2016 | 6/30/2015 | 6/30/2014 | ||
|---|---|---|---|---|---|---|---|
| Net loss: | (4,919) | (16,013) | (2,424) | (2,940) | (3,369) | ||
| Comprehensive loss, net of tax, attributable to parent: | (4,919) | (16,013) | (2,424) | (2,940) | (3,369) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.